The role of IGF-1R in pediatric malignancies

Oncologist

Volumn 14, Issue 1, 2009, Pages 83-91

  Kim, Su Young ^a   Toretsky, Jeffrey A ^b   Scher, Daniel ^b   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

IGF 1R; Molecular targeting; Pediatric malignancy; Therapeutic antibody

Indexed keywords

ADW 742; AMG 479; AVE 1642; BIIB 022; CP 751871; IMATINIB; IMCA 12; INSULIN; INSULIN RECEPTOR; MK 0646; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHA IR3; NVPAEW 541; OCTREOTIDE; PEGVISOMANT; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; SCH 717454; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR MONOCLONAL ANTIBODY; SOMATOMEDIN RECEPTOR; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CARCINOGENESIS; CHILDHOOD CANCER; DRUG TARGETING; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEPATOBLASTOMA; HUMAN; HYPERGLYCEMIA; NEPHROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RETINOBLASTOMA; RHABDOMYOSARCOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHILD; HUMANS; MICE; MUTATION; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 61449097712     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0189     Document Type: Article

References (70)

1. Pollak MN, Schemhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.
2. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
3. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: A preliminary report. Growth Horm IGF Res 2007;17:54-57.
4. Yakar S, Wu Y, Setser J et al. The role of circulating IGF-I: Lessons from human and animal models. Endocrine 2002;19:239-248.
5. Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008;19:111-120.
6. Minniti CP, Tsokos M, Newton WA Jr et al. Specific expression of insulinlike growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 1994;101:198-203.
7. Yun K, Molenaar AJ, Fiedler AM et al. Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney. Lab Invest 1993;69:603-615.
8. El-Badry OM, Romanus JA, Helman LJ et al. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest 1989;84:829-839.
9. Bach LA, Headey SJ, Norton RS. IGF-binding proteins-the pieces are falling into place. Trends Endocrinol Metab 2005;16:228-234.
10. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: Implications for drug design. Nat Rev Drug Discov 2002;1:769-783.
11. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-1 receptors in human cancer. Curr Pharm Des 2007;13:671-686.
12. O'Gorman DB, Costello M, Weiss J et al. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res 1999;59:5692-5694.
13. Adams TE, Epa VC, Garrett TPJ et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000;57:1050-1093.
14. Butler AA, Yakar S, Gewolb IH et al. Insulin-like growth factor-I receptor signal transduction: At the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol 1998;121:19-26.
15. Dearth RK, Cui X, Kim HJ et al. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007;6:705-713.
16. Cao L, Yu Y, Darko I et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68: 8039-8048.
17. Pollak M, Sem AW, Richard M et al. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992;84: 966-971.
18. Mansky PJ, Liewehr DJ, Steinberg SM et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: Significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol 2002; 24:440-446.
19. Khanna C, Prehn J, Hayden D et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: Evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 2002; 8:2406-2412.
20. Yin D, Vreeland F, Schaaf LJ et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy. Clin Cancer Res 2007;13:1000-1009.
21. Feng Y, Zhu Z, Xiao X et al. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006;5:114-120.
22. Resnicoff M, Sell C, Rubini M et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are non-tumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54:2218-2222.
23. Rininsland F, Johnson TR, Chemicky CL et al. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci U S A 1997;94:5854-5859.
24. Putral LN, Gu W, McMillan NAJ. RNA interference for the treatment of cancer. Drug News Perspect 2006;19:317-324.
25. García-Echeverría C, Pearson MA, Marti A et al. In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231-239.
26. Scotlandi K, Manara MC, Nicoletti G et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-3876.
27. Tanno B, Mancini C, Vitali R et al. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 2006;12:6772-6780.
28. Martins AS, Mackintosh C, Martin DH et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12:3532-3540.
29. Pollak MN, Polychronakos C, Richard M. Insulinlike growth factor I: A potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990:82: 301-305.
30. Scotlandi K, Benini S, Nanni P et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998;58:4127-4131.
31. Feng Y, Dimitrov DS. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 2008;11: 178-185.
32. Kolb EA, Gorlick R, Houghton PJ et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-1197.
33. Rodon J, Patnaik A, Stein M et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 2007;25(18 suppl):3590.
34. Higano CS, Yu EY, Whiting SH et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-1 receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2007;25(18 suppl):3505.
35. Tolcher AW, Rothenberg ML, Rodon J et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007;25(18 suppl):3002.
36. Atzori F, Tabernero J, Cervantes A et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008;26:(15 suppl): 3519.
37. Owen LA, Lessnick SL. Identification of target genes in their native cellular context: An analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle 2006;5: 2049-2053.
38. Scotlandi K, Benini S, Sarti M et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res 1996;56:4570-4574.
39. Yee D, Favoni RE, Lebovic GS et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation: A potential autocrine growth factor. J Clin Invest 1990;86:1806-1814.
40. Toretsky JA, Kalebic T, Blakesley V et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-30827.
41. Toretsky JA, Steinberg SM, Thakar M et al. Insulin-like growth factor type 1 (IGF-1 ) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001;92:2941-2947.
42. Prieur A, Tirode F, Cohen P et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-7283.
43. Benini S, Manara MC, Cerisano V et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. Int J Cancer 2004;108:358-366.
44. Toretsky JA, Thakar M, Eskenazi AE et al. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res 1999;59:5745-5750.
45. Zhan S, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995;11:2503-2507.
46. El-Badry OM, Minniti C, Kohn EC et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-331.
47. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94:445-448.
48. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-297.
49. Gallicchio MA, van Sinderen M, Bach LA. Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res 2003;35:822-827.
50. Wan X, Harkavy B, Shen N et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-1940.
51. Kappel CC, Velez-Yanguas MC, Hirschfeld S et al. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994;54:2803-2807.
52. Burrow S, Andrulis IL, Pollak M et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma J Surg Oncol 1998;69:21-27.
53. Raile K, Hoflich A, Kessler U et al. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: Autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 1994;159:531-541.
54. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST) update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(suppl 2):S1-S31.
55. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
56. Demetri GD, van Oosteram AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006:368;1329-1338.
57. Agaram NP, Laquaglia MP, Ustun B et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008:14:3204-3215.
58. Janeway KA, Liegl B, Harlow A et al. Pediatric KIT wild-type and platelet-derived growth factor α-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gas-trointestinal stromal tumors. Cancer Res 2007;67:9084-9088.
59. Reeve AE, Eccles MR, Wilkins RJ et al. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 1985;317:258-260.
60. Scott J, Cowell J, Robertson ME et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature 1985;317: 260-262.
61. Rainier S, Johnson LA, Dobry CJ et al. Relaxation of imprinted genes in human cancer. Nature 1993;362:747-749.
62. Ogawa O, Eccles MR, Szeto J et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993;362:749-751.
63. Bjornsson HT, Brown LJ, Fallin MD et al. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 2007;99: 1270-1273.
64. Gansler T, Allen KD, Burant CF et al. Detection of type 1 insulinlike growth factor (IGF) receptors in Wilms' tumors. Am J Pathol 1988;130: 431-435.
65. Werner H, Re GG, Drummond IA et al. Increased expression of the insulinlike growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product Proc Natl Acad Sci U S A 1993;90:5828-5832.
66. Werner H, Shen-Orr Z, Rauscher FJ 3rd et al. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 1995;15:3516-3522.
67. Natrajan R, Reis-Filho JS, Little SE et al. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. Cancer Res 2006;66:11148-11155.
68. El-Badry OM, Helman LJ, Chatten J et al. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest 1991;87: 648-657.
69. Gray SG, Eriksson T, Ekström C et al. Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 2000;82:1561-1567.
70. Giuliano M, Vento R, LauricellaM et al. Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells. Eur J Biochem 1996;236:523-532.